Real-World Data Confirm Efficacy of Axi-cel Across Patient-Related Factors in R/R LBCL
Bexobrutideg Is Safe, Shows Early Efficacy in Relapsed/Refractory CLL
Asciminib Shows Superior Tolerability Over Nilotinib in Newly Diagnosed CML in Chronic Phase
ESAs or Danazol Plus Ruxolitinib Produce Comparable Spleen and Symptom Response Rates in Myelofibrosis With Anemia
